Frenetic 12 Months For SkyePharma
Chairman and chief executive of SkyePharma of the UK, Ian Gowrie-Smith, described the firm's activities as frenetic when he spoke at a London press briefing on the results for the 12 months ended July 31, 1996.
The last 12 months were devoted to the restructuring of the the firm to focus on what is SkyePharma's two-pronged strategy of applying drug delivery technologies to new formulations and exploiting niche generic drug opportunities in the USA.
The original tent hire business of Black & Edgington has been disposed of, and two acquisitions have been made; that of Jago Holding and Krypton Ltd.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze